Showing results (291-300 of 354) with videos related to

Sort By:
Pageof 36
Clinical Chemistry|May 17, 2015
Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancerDavid S Guttery, Karen Page, Allison Hills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
[11C]choline positron emission tomography in estrogen receptor-positive breast cancerKaiyumars B Contractor, Laura M Kenny, Justin Stebbing, et al.
Plos One|November 9, 2013
Influence of plasma processing on recovery and analysis of circulating nucleic acidsKaren Page, David S Guttery, Nathalie Zahra, et al.
Breast Cancer Research and Treatment|June 20, 2021
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trialJustin Stebbing, Yauheni V Baranau, Valery Baryash, et al.
Cancer Research|August 10, 2013
Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferationFilipa G Pinho, Adam E Frampton, Joao Nunes, et al.
Physics in Medicine and Biology|May 11, 2012
Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapyKaiyumars Contractor, Amarnath Challapalli, Giampaolo Tomasi, et al.
EMBO Molecular Medicine|July 1, 2022
A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyondShiran Shapira, Marina Ben Shimon, Mori Hay-Levi, et al.
Clinical Chemistry|December 13, 2016
Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast CancerKaren Page, David S Guttery, Daniel Fernandez-Garcia, et al.
Oncotarget|May 4, 2018
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burdenAdam E Frampton, Mireia Mato Prado, Elena López-Jiménez, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 7, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled TrialJustin Stebbing, Yauheni Baranau, Valery Baryash, et al.
Pageof 36